12 pending office actions • 4 clients
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 6 |
| DANA-FARBER CANCER INSTITUTE, INC. | 3 |
| Allergan Pharmaceuticals International Limited | 2 |
| New York University | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18690160 | POTENT AND SELECTIVE INHIBITORS OF IRAK4 | DANA-FARBER CANCER INSTITUTE, INC. | KOSTURKO, GEORGE W | 1621 | Non-Final OA | Mar 07, 2024 |
| 18549127 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Sep 05, 2023 |
| 18215098 | DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATION | Allergan Pharmaceuticals International Limited | MAEWALL, SNIGDHA | 1612 | Final Rejection | Jun 27, 2023 |
| 18191589 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | ISMAIL, REHANA | 1625 | Non-Final OA | Mar 28, 2023 |
| 18189092 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | Non-Final OA | Mar 23, 2023 |
| 18044462 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. | ROMERO, KRISTEN WANG | 1624 | Final Rejection | Mar 08, 2023 |
| 17802896 | MAP KINASE KINASE (MKK7) INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | HIRAKIS, SOPHIA P | 1623 | Final Rejection | Aug 26, 2022 |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | New York University | SCHMIDT, IZABELA MARIA | 1621 | Final Rejection | Jun 24, 2022 |
| 17789023 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | ADLAM, CHANTAL PETA-GAYE | 1622 | Non-Final OA | Jun 24, 2022 |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | CORNET, JEAN P | 1628 | Non-Final OA | Jan 20, 2022 |
| 17596466 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | SEITZ, ANTHONY JOSEPH | 1629 | Final Rejection | Dec 10, 2021 |
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | Allergan Pharmaceuticals International Limited | MARTIN, PAUL C | 1653 | Non-Final OA | Sep 03, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial